ArticleScientific reports2025
Evaluation of serum alkaline phosphatase and lactate dehydrogenase as predictive biomarkers for the prognosis of male breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Assessing the hepatic and renal parameters of breast cancer patient blood samples before and after chemotherapy.Toxicology reports · 2026Article
- The prognostic value of peripheral blood inflammatory markers in patients with HER2-positive metastatic breast cancer treated with pyrotinib.Frontiers in oncology · 2026Article
- Unlocking the potential: current landscape and future directions of immunotherapy in gastric cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Breast cancer has become one of the most common malignant tumors in women, and the incidence rate is increasing annually in men. This study focused on exploring the prognostic significance of the combined detection of serum ALP and LDH in patients with breast cancer. We enrolled 80 individuals with male breast cancer (MBC), female breast cancers (FBCs) were randomly matched via propensity score matching (PSM). In the MBC cohort, the optimal cutoff values for ALP and LDH were determined to be 114 U/L and 207 U/L, respectively, whereas in the FBC cohort, they were 68 U/L and 133 U/L, respectively. There was a difference in median survival between patient groups classified by the optimal cutoff values of ALP and LDH in the FBC cohort. However, in the FBC cohort, there was no significant correlation between the levels of ALP or LDH and patient prognosis. We developed a "joint score" system that incorporates the values of both ALP and LDH and separates MBCs into three groups. Survival was significantly different among the three groups. In the multivariate analysis, the "joint score" was identified as an independent prognostic factor for both disease-free survival(DFS) and overall survival (OS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.